Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Takeda Pharmaceutical Ltd ADR (NY: TAK ) 14.89 +0.00 (+0.03%) Streaming Delayed Price Updated: 2:19 PM EDT, Sep 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Takeda Pharmaceutical Ltd ADR < Previous 1 2 3 4 5 6 7 Next > New Study Reveals How Classical Music Could Revolutionize Depression Care August 12, 2024 In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... Via PressReach Exposures Product Safety Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP) August 07, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline July 31, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces New Assignments of Directors June 26, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies June 24, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia June 22, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer June 21, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda June 21, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting June 18, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome June 17, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI) June 14, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts June 11, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo June 03, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma June 01, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP) May 31, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting May 14, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease May 13, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion May 09, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer April 26, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda April 26, 2024 From HUTCHMED (China) Limited Via GlobeNewswire U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease April 18, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food April 08, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting March 26, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) March 26, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL March 19, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders March 19, 2024 From Centogene NV Via GlobeNewswire Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia March 13, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas February 26, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) February 12, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024 February 08, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.